CJC-1295 Pipeline and Next-Gen Growth Hormone Secretagogues

CJC-1295 Has No FDA Approval and No Approved Label

CJC-1295 is not an FDA-approved drug. No new drug application (NDA) or biologics license application (BLA) has ever been submitted for this compound to the FDA. The Drugs@FDA database returns zero results for CJC-1295 under any trade name.

The peptide was originally developed by ConjuChem Biotechnologies (later ConjuChem LLC, Montreal) as a long-acting growth hormone-releasing factor (GRF) analogue. It is a synthetic 30-amino-acid peptide corresponding to GRF(1-29) with four amino acid substitutions to resist DPP-IV cleavage, conjugated to a drug affinity complex (DAC) that binds albumin and extends the half-life from minutes to approximately 5.8 to 8.1 days [1]. Teichman et al. published the key Phase II pharmacokinetic and pharmacodynamic data in the Journal of Clinical Endocrinology & Metabolism in 2006, showing dose-dependent GH and IGF-1 increases with weekly or biweekly subcutaneous dosing.

ConjuChem's development program did not advance to Phase III. The company's pipeline stalled after financial difficulties and a reported treatment-related death during early clinical studies. No other pharmaceutical sponsor has picked up the compound for IND-track development. Because no approval exists, there is no FDA-approved label, no official prescribing information, and no mandated Risk Evaluation and Mitigation Strategy (REMS) for CJC-1295.

How CJC-1295 Is Currently Sourced

Without commercial manufacturing, CJC-1295 reaches patients exclusively through compounding pharmacies. This is a critical regulatory distinction.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription. Under Section 503B, outsourcing facilities may produce compounded drugs without patient-specific prescriptions but must register with the FDA and comply with current good manufacturing practice (cGMP) standards.

CJC-1295 appears on compounding pharmacy catalogs typically as "CJC-1295/Ipamorelin" combination vials for subcutaneous injection. The purity, potency, and sterility of these products depend entirely on the compounding facility's quality systems. The FDA does not review compounded products for safety or efficacy before they reach patients. A 2023 FDA safety communication reminded consumers that compounded drugs are not FDA-approved and may carry additional risks.

The distinction matters for clinicians. A provider prescribing CJC-1295 from a 503A pharmacy is operating within a regulatory allowance, not under an FDA indication. Documentation should reflect off-label or investigational use, and patients should be informed that the product has not undergone the standard FDA review process for marketed drugs.

The Phase II Data That Defined CJC-1295 Pharmacology

The most cited clinical evidence for CJC-1295 comes from a single Phase II, randomized, placebo-controlled, dose-escalation study in 56 healthy adults aged 21 to 61 [1].

Teichman et al. administered single subcutaneous doses of 30, 60, or 90 mcg/kg CJC-1295 DAC and measured GH and IGF-1 over 28 days. Key findings from the 2006 publication:

• Mean GH levels increased 2- to 10-fold for at least 6 days after a single 60 mcg/kg injection.
• IGF-1 levels rose 1.5- to 3-fold and remained elevated for 8 to 14 days depending on the dose.
• The 90 mcg/kg dose produced the highest peak IGF-1 but also the most injection-site reactions.
• No anti-CJC-1295 antibodies were detected after up to four weekly injections.

These results demonstrated that DAC-conjugated GRF(1-29) could produce sustained, pulsatile GH secretion from a single weekly injection, a pharmacokinetic profile distinctly different from daily GH injections like somatropin. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults, however, did not include CJC-1295 in its treatment recommendations because no Phase III efficacy or long-term safety data existed.

Safety Signals and Why the Pipeline Stalled

The absence of Phase III data is not simply an economic story. Safety concerns contributed to the halt.

During ConjuChem's early clinical program, one subject death was reported in association with CJC-1295 administration. Details were disclosed in regulatory filings but not published in a peer-reviewed journal. The death, combined with the company's limited capital, effectively ended further development. No sponsor has filed a new IND for CJC-1295 since.

Known adverse effects from the Phase II trial included injection-site erythema and induration (reported in 8 of 43 active-treatment subjects), transient flushing, and headache [1]. GH-related side effects, specifically fluid retention, arthralgias, and carpal tunnel-like symptoms, were not systematically reported in the short 28-day observation window but are expected class effects of sustained GH elevation based on data from recombinant GH studies published in the New England Journal of Medicine.

Long-term safety data simply do not exist for CJC-1295. There is no post-marketing surveillance system, no FAERS (FDA Adverse Event Reporting System) signal database specific to this compound, and no Sentinel System monitoring because the drug was never approved. Clinicians prescribing CJC-1295 through compounding pharmacies are generating real-world data without any centralized collection mechanism.

The Endocrine Society has not issued specific guidance on compounded GH secretagogues, and the American Association of Clinical Endocrinology (AACE) published a 2019 position statement emphasizing that GH therapy should use FDA-approved formulations with established safety profiles.

What "CJC-1295 Without DAC" Actually Is

A source of confusion in the peptide market is the term "CJC-1295 without DAC," also called "mod GRF(1-29)" or "modified GRF 1-29." This is not the same compound studied by Teichman et al.

CJC-1295 without DAC is simply the modified GRF(1-29) peptide (tetrasubstituted to resist enzymatic degradation) but lacking the drug affinity complex that provides albumin binding and the multi-day half-life. Without DAC, the peptide's half-life drops to roughly 30 minutes, requiring multiple daily injections to maintain GH pulses.

No clinical trial has ever evaluated "CJC-1295 without DAC" as a defined pharmaceutical product. The dosing protocols used in clinical practice (typically 100 mcg subcutaneously two to three times daily, often co-administered with a GHRP like ipamorelin) are derived from extrapolation, not from controlled studies. The NIH Clinical Trials registry lists no active or completed studies under this name.

This is a meaningful distinction: the Phase II safety and efficacy data apply only to the DAC-conjugated form. Providers and patients referencing "CJC-1295 data" to justify non-DAC formulations are applying evidence across pharmacologically different molecules.

FDA Enforcement and the 2023 Peptide Crackdown

The FDA has increased scrutiny of compounded peptides, and CJC-1295 sits squarely in this enforcement zone.

In late 2023, the FDA proposed updates to the list of bulk drug substances that can be used in compounding under Section 503B. Several peptides were flagged for removal from the nominated bulks list, meaning outsourcing facilities would lose the ability to compound them. While CJC-1295 was not specifically named in the initial category 1 or category 2 lists (as tirzepatide and semaglutide were), the regulatory trajectory is clear: peptides without adequate safety data face an increasingly narrow path through compounding channels.

The FDA's compounding policy page outlines the evaluation criteria. A bulk substance must demonstrate adequate published safety and efficacy data to remain eligible for 503B compounding. CJC-1295's data package (one Phase II study, no Phase III, no long-term follow-up, one death in clinical development) is thin by any regulatory standard.

Clinicians should monitor the FDA's bulks list updates for any future inclusion of CJC-1295 in a restricted category. A removal from the 503B bulks list would not affect 503A patient-specific compounding directly but would signal regulatory concern.

Next-Generation GH Secretagogues in Development

The clinical need that CJC-1295 addresses, sustained GH pulsatility from a non-daily injectable or oral formulation, has not disappeared. Several next-generation compounds target this space.

Macimorelin (Macrilen) is the only FDA-approved GH secretagogue, but it is indicated solely as a diagnostic agent for adult GH deficiency, not for treatment. Approved in 2017, macimorelin is an oral ghrelin-receptor agonist that stimulates GH release. Its approval demonstrated that oral GH secretagogues can pass FDA review, but therapeutic applications were never pursued by the sponsor.

Oral GH secretagogue candidates in preclinical or early clinical development include nonpeptide ghrelin-receptor agonists designed for daily oral dosing. None has reached Phase II for a therapeutic indication as of May 2026. Published data remain limited to conference abstracts and preclinical models.

Long-acting somatropin formulations have largely overtaken the secretagogue approach for GH replacement. Somapacitan (Sogroya), an FDA-approved once-weekly GH analogue, and lonapegsomatropin (Skytrofa), an FDA-approved weekly GH for pediatric GH deficiency, offer the same dosing convenience that CJC-1295 DAC promised but with full regulatory approval and post-marketing safety systems. The FDA approval of somapacitan in 2020 for adult GH deficiency effectively addressed the unmet need for reduced injection frequency.

For clinicians considering GH optimization strategies, the approved long-acting somatropin products provide a regulatory and evidentiary standard that CJC-1295 cannot match. The practical question is whether CJC-1295's mechanism (stimulating endogenous pulsatile GH release rather than replacing GH exogenously) offers a physiologic advantage. No head-to-head trial has been conducted.

What This Means for Clinicians Prescribing CJC-1295 Today

Providers using CJC-1295 in clinical practice operate outside FDA-approved pathways. That is a legal reality, not a clinical judgment.

The prescribing framework should include: verification that the compounding pharmacy holds a valid state license and (if 503B) FDA registration; documentation of the clinical rationale for choosing a non-approved secretagogue over approved GH products; informed consent that explicitly states the drug is not FDA-approved, the safety data are limited, and there is no standardized manufacturing quality; baseline and serial IGF-1 monitoring (every 8 to 12 weeks per Endocrine Society guidelines for GH therapy); and a defined stopping protocol if IGF-1 exceeds the age-adjusted upper limit of normal.

"Patients receiving compounded GH-releasing peptides should be monitored with the same rigor as those on approved GH therapy," states the Endocrine Society's 2011 guideline on adult GH deficiency, referencing the broader principle that GH-axis stimulation carries dose-dependent risks regardless of the specific agent used [2].

Dr. George Merriam, writing in the Journal of Clinical Endocrinology & Metabolism, noted that CJC-1295 DAC "produced prolonged and dose-dependent increases in GH and IGF-1 without serious adverse events in the dose range studied," but cautioned that "longer and larger trials are needed before therapeutic use can be recommended."

Until a sponsor initiates a Phase III program or the FDA explicitly restricts compounding access, CJC-1295 will remain in a regulatory gray zone: available but unapproved, used but unstudied at scale, and prescribed under clinician judgment without the safety infrastructure that FDA-approved drugs provide. Providers should document IGF-1 levels at baseline, 8 weeks, and 16 weeks after initiation, and discontinue if IGF-1 exceeds 1.5 times the age-adjusted upper limit of normal.